Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 5/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 11/20 | 0.44 |
| ▸ | FPR2 | P25090 | 5/20 | 0.43 |
| ▸ | FFAR2 | O15552 | 2/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.40 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12973275 | 0.83 | KCNH2 (0.45) | KCNH2PARP10SCN9AFPR2FFAR2 | |
| SCHEMBL2835462 | 0.79 | KCNH2 (0.57) | KCNH2SCN9AFFAR2SCN3A | |
| SCHEMBL2713204 | 0.79 | KCNH2 (0.39) | KCNH2FFAR2 | |
| SCHEMBL2712967 | 0.79 | KCNH2 (0.39) | KCNH2FFAR2 | |
| SCHEMBL4759457 | 0.79 | KCNH2 (0.39) | KCNH2FFAR2 | |
| SCHEMBL2714031 | 0.79 | KCNH2 (0.39) | KCNH2FFAR2 | |
| SCHEMBL20835720 | 0.79 | FFAR2 (0.42) | KCNH2FFAR2 | |
| SCHEMBL2714986 | 0.77 | KCNH2 (0.76) | KCNH2PARP10SCN9AFFAR2PARP14 | |
| SCHEMBL2712421 | 0.77 | KCNH2 (0.76) | KCNH2PARP10SCN9AFFAR2PARP14 | |
| SCHEMBL2712355 | 0.77 | KCNH2 (0.76) | KCNH2PARP10SCN9AFFAR2PARP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855218-B2 | (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide; depression or a mood disorder ; modulation of use-dependent voltage-gated sodium channels | Convergence Pharmaceuticals Limited (GB) | 2010-12-21 | — | — | US | disclosed |
| EP-1943216-B1 | PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS | GLAXO GROUP LTD (GB) | 2010-06-30 | — | — | EP | disclosed |
| US-20080306122-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306122-A1 | Novel Compounds | CYP11B1, CYP11B2, CYP46A1 | KCNH2 3313/4885PARP10 1503/4885SCN9A 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.